Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 2282

Next Previous
Drug Profile

REC 2282

Alternative Names: AR-42; NSC-D736012; OSU-HDAC42; REC-2282

Latest Information Update: 29 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Recursion Pharmaceuticals; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Neurofibromatosis 2
  • No development reported Acute myeloid leukaemia
  • Discontinued Bladder cancer; Chronic lymphocytic leukaemia; Lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
  • 23 Aug 2024 Recursion Pharmaceuticals and Exscientia agree to co-promote and co-develop REC 2282 for Neurofiibrosis type 2
  • 04 May 2023 REC 2282 receives Orphan Drug status for Neurofibromatosis 2 in USA, prior to May 2203

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top